Dr Paul Huang’s team aims to understand how networks of signalling-proteins control tumour progression and drug resistance in cancer.
Dr Paul Huang uses systems biology and molecular pathology to study drug resistance in sarcomas and lung cancer. He trained at Imperial College London and Massachusetts Institute of Technology, and was awarded a Sir Henry Wellcome Fellowship in 2009 and a Cancer Research UK Career Establishment Award in 2015.
I am a higher scientific officer. My work involves Nanostring gene expression analysis to establish molecular signatures or biomarkers for targeted therapy response in sarcoma trials.
I am PhD student focusing on understanding angiosarcomas. My work involves molecular profiling of angiosarcoma patient samples to better understand mechanisms of treatment response and resistance and identify potential biomarkers.
I am currently working on utilising radiogenomics to understand heterogeneity and therapy response in soft tissue sarcoma, and whether combining imaging and molecular data can improve patient outcomes.
I am a PhD student and my work will be focussed on analysing post translational modifications, particularly phosphoproteomics by mass spectrometry in soft tissue sarcomas.
My research aims to identify candidate biomarkers for improving neoadjuvant therapy in high-risk soft tissue sarcomas. This convergence science project uses an explant-in-chip model developed by the Overby group, our collaborators at Imperial College London.
I am an administrative assistant within the Division of Molecular Pathology. I have a keen interest in the world of oncology and am enthusiastic about supporting those who are making a real difference in their work.
I began my postdoctoral career at the ICR in 2015. Initially working for the Signal Transduction Team (Barbara Tanos) and subsequently joining the Molecular and Systems Oncology Team in 2018. My current research is focused on understanding sub-clonal interactions and tumour heterogeneity driving EGFR inhibitor resistance in lung cancer.
I am a first-year PhD student split between Imperial College London (Ishihara lab) and the Institute of Cancer Research (Huang lab). My research will be focused on the bioengineering and development of immunomodulatory agents designed to target the extracellular matrix as a novel therapeutic strategy to treat sarcoma.
I am a Scientific Officer in the lab, working on tackling EGFR Exon 20 mutations in lung cancer.
I am interested in the proteomics of the extracellular matrix during breast cancer progression and in SWATH mass spectrometry development for clinical proteomics.
I am a Higher Scientific Officer currently investigating the drug resistance mechanisms in lung cancer patients with EGFR Exon20 insertion mutations using gene editing approaches such as CRISPR-Cas9.
I am a fourth year PhD student and I’ll be using proteomics to better understand mechanisms of chemoresistance in soft tissue sarcoma (STS), characterising extracellular proteins and associated proteins (matrisome) to do this.
I am a PhD student working to understand the mechanisms of response and resistance in alveolar soft part sarcoma to the TKI cediranib, with the aims of identifying new biomarkers and therapeutic strategies to improve patient outcome.